Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study

Conclusions
This pharmacovigilance study serves as a clinical reminder to physicians to be more vigilant for fluid retention-associated AEs with BCR::ABL inhibitors.

Source: BMJ Open - August 3, 2023 Category: General Medicine Authors: Huang, J., Cai, J., Ye, Q., Jiang, Q., Lin, H., Wu, L. Tags: Open access, Pharmacology and therapeutics Source Type: research